Safety of using genetic engineering biological agents in rheumatoid arthritis

The paper reviews the current trials of the safety of using genetic engineering biological agents (GEBA) in patients with rheumatoid arthritis. It is stated that before its start, GEBA therapy calls for thorough screening of patients to rule out communicable diseases (including tuberculosis) or a hi...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Современная ревматология
المؤلفون الرئيسيون:	N V Chichasova, E L Nasonov
التنسيق:	مقال
اللغة:	الروسية
منشور في:	IMA-PRESS LLC 2010-03-01
الموضوعات:	rheumatoid arthritis genetic engineering biological agents
الوصول للمادة أونلاين:	https://mrj.ima-press.net/mrj/article/view/272

مواد مشابهة

Combination therapy with leflunomide and genetic engineering biological agents
حسب: Nataliya Vladimirovna Chichasova, وآخرون
منشور في: (2011-06-01)

USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS
حسب: E L Nasonov, وآخرون
منشور في: (2010-03-01)

Severe rheumatoid arthritis with multiple baseline anti-inflammatory drugs intolerance
حسب: D. A. Kusevich, وآخرون
منشور في: (2016-12-01)

Possible reasons for the inefficacy of genetically engineered biological agents in rheumatoid arthritis and ways of its prevention
حسب: Natalia Vladimirovna Chichasova
منشور في: (2012-06-01)

METHOTREXATE IN RHEUMATOID ARTHRITIS – 2015: NEW FACTS AND IDEAS
حسب: E. L. Nasonov
منشور في: (2015-09-01)

METHOTREXATE IN RHEUMATOID ARTHRITIS – 2015: NEW FACTS AND IDEAS
حسب: E. L. Nasonov
منشور في: (2016-12-01)

PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS: NEW STRATEGY, NEW TARGETS
حسب: E. L. Nasonov
منشور في: (2017-09-01)

METHOTREXATE IN RHEUMATOID ARTHRITIS – 2015: NEW FACTS AND IDEAS
حسب: E. L. Nasonov
منشور في: (2015-10-01)

PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS: RUSSIAN AND INTERNATIONAL GUIDELINES
حسب: E. L. Nasonov
منشور في: (2016-12-01)

NEW RECOMMENDATIONS FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE ROLE OF METHOTREXATE
حسب: Evgeniy L Nasonov, وآخرون
منشور في: (2014-03-01)

EULAR RECOMMENDATIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS – 2013: GENERAL CHARACTERISTICS AND DISPUTABLE PROBLEMS
حسب: E. L. Nasonov, وآخرون
منشور في: (2015-10-01)

EULAR RECOMMENDATIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS – 2013: GENERAL CHARACTERISTICS AND DISPUTABLE PROBLEMS
حسب: Evgenii Lvovich Nasonov, وآخرون
منشور في: (2014-02-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
حسب: Natalia Vladimirovna Chichasova
منشور في: (2014-12-01)

RHEUMATOID ARTHRITIS: PROBLEMS AND SIGNIFICANCE OF PERSONALIZED MEDICINE
حسب: E L Nasonov
منشور في: (2012-05-01)

Biological agents for endoprosthetic joint replacement in patients with rheumatoid arthritis
حسب: Viktoria Nikolaevna Khlaboshina, وآخرون
منشور في: (2014-12-01)

IMPACT OF BIOLOGICAL THERAPY ON BONE IN PATIENTS WITH RHEUMATOID ARTHRITIS
حسب: P. S. Dydykina, وآخرون
منشور في: (2014-12-01)

WHY ARE THE RECOMMENDED METHOTREXATE DOSES NOT USED FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: WHO IS GUILTY AND WHAT TO DO?
حسب: Yu. V. Muravyev, وآخرون
منشور في: (2017-03-01)

Rheumatoid arthritis: problems of treatment at the present stage
حسب: N. V. Chichasova
منشور في: (2018-12-01)

POSSIBILITIES FOR PRESERVING THE RESULTS OF TREATMENT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER DOSE REDUCTION AND/OR DISCONTINUATION OF BIOLOGICAL AGENTS: A REMARCA STUDY
حسب: E. L. Luchikhina, وآخرون
منشور في: (2016-12-01)

Functional outcomes of rheumatoid arthritis during various proceduresof anti-inflammatory therapy
حسب: Natalya Vladimirovna Chichasova, وآخرون
منشور في: (2010-04-01)

Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia
حسب: Irina Mikhailovna Marusenko
منشور في: (2013-12-01)

INFLIXIMAB (REMICADE): POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
حسب: Nataliya Vladimirovna Chichasova, وآخرون
منشور في: (2011-03-01)

INFLIXIMAB (REMICADE): POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
حسب: Nataliya Vladimirovna Chichasova, وآخرون
منشور في: (2011-03-01)

Rheumatology in Russia in the early 21st century
حسب: E L Nasonov
منشور في: (2013-05-01)

ROLE OF MATRIX METALLOPROTEINASE 3 IN PREDICTING THE EFFICIENCY OF THERAPY FOR EARLY RHEUMATOID ARTHRITIS: THE REMARCA TRIAL
حسب: A. S. Avdeeva, وآخرون
منشور في: (2016-03-01)

Pharmacoeconomic analysis of using biological agents in the treatment of rheumatoid arthritis
حسب: I. I. Dyakov, وآخرون
منشور في: (2014-09-01)

Rheumatoid arthritis in real clinical practice: initiation of therapy with biological agents. Results of the «Computer Terminals of Self-Assessment for Patients with Rheumatic Diseases» («TERMINAL-II») project
حسب: V. N. Amirdzhanova, وآخرون
منشور في: (2019-09-01)

CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS: LATEST DATA
حسب: T. V. Popkova, وآخرون
منشور في: (2016-07-01)

The place of tumor necrosis factor alpha inhibitors in the treatment of rheumatoid arthritis patients: tactics in different variants of the disease
حسب: N. V. Chichasova
منشور في: (2015-12-01)

EULAR recommendation for the management of rheumatoid arthritis (2013): glucocorticoid use
حسب: N.V. Chichasova
منشور في: (2014-05-01)

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
حسب: E. L. Nasonov, وآخرون
منشور في: (2022-11-01)

Safety and efficiency of therapy by gene-engineering-biological preparations of rheumatoid arthritis
حسب: E. A. Strel’tsov
منشور في: (2018-10-01)

CLINICAL SIGNIFICANCE OF BAFF/BLyS AND APRIL IN SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS
حسب: E. V. Suponitskya, وآخرون
منشور في: (2014-10-01)

Comparative clinical characteristics of untreated early rheumatoid arthritis in patients with early and late onset according to the All-Russian Register of Patients with Arthritis “OREL”
حسب: A. M. Satybaldyev, وآخرون
منشور في: (2022-03-01)

Determination of recombinant biological agents requirement for patients with rheumatoid arthritis: development of standardized indications for prescription
حسب: M Y Telnyh, وآخرون
منشور في: (2009-12-01)

INTERLEUKIN-17 IS A NEW TARGET FOR ANTI-CYTOKINE THERAPY OF IMMUNE INFLAMMATORY RHEUMATIC DISEASES
حسب: Evgeny Lvovich Nasonov, وآخرون
منشور في: (2013-12-01)

BIOSIMILARS IN RHEUMATOLOGY
حسب: E. L. Nasonov
منشور في: (2017-01-01)

Bioanalogues in the treatment of rheumatoid arthritis: current status of the problem
حسب: N. V. Chichasova, وآخرون
منشور في: (2024-12-01)

The role of etanercept in the treatment of patients with severe rheumatoid arthritis
حسب: N. V. Chichasova
منشور في: (2013-12-01)

Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice
حسب: D. A. Kusevich, وآخرون
منشور في: (2019-01-01)